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E-mail address: Rajendra.Kumar-Singh@tufts.edu (Recently we described a novel cell penetrating peptide, peptide for ocular delivery (POD) that could deli-
ver small molecules including ﬂuorescent dyes into retinal cells. The objective of the current study was to
examine whether biologically relevant macromolecules such as proteins, genetically fused with POD
could also be delivered into retinal tissues in vivo. We generated a POD–GFP fusion protein and examined
its cell and tissue penetrating properties. We found that endogenously expressed POD–GFP fusion protein
localized to the nucleus, suggesting that POD acts as a nuclear localization signal. Adenovirus (Ad) vectors
expressing POD–GFP fusion protein were constructed and the recombinant protein was puriﬁed from Ad-
infected human embryonic retinoblasts (HER). Exogenously supplied POD–GFP fusion protein rapidly
transduced A549 and HER cells and colocalized in part with markers of late endosomes, from which it
could escape. Following subretinal delivery, POD–GFP localized to the retinal pigment epithelium and
the photoreceptor cell bodies. When injected into the vitreous, POD–GFP localized to the ganglion cells
and the inner nuclear layer of the retina as well as the lens capsule. Topical application of POD–GFP to
ocular surfaces resulted in uptake by the corneal epithelium. POD–GFP also transduced non-ocular tis-
sues, including the epidermis of the skin following topical application.
 2009 Elsevier Ltd. All rights reserved.1. Introduction
According to public opinion polls, blindness is the second most
feared condition amongst Americans after cancer. Almost 200
different loci and 130 different genes responsible for inherited ret-
inal degeneration have thus far been identiﬁed, making retinal
degeneration one of the most heterogeneous genetic disorders in
humans (www.retnet.org). A large number of these genes are
expressed exclusively in the photoreceptors or retinal neurons.
Efﬁcient delivery of therapeutic proteins into retinal cells is cur-
rently limited to the use of recombinant viruses for delivery of
DNA expression cassettes – an approach that in some tissues can
be deleterious (Donsante et al., 2007). Hence, relatively intensive
and signiﬁcantly protracted preclinical studies need to be per-
formed prior to the use of gene delivery in humans. Given the large
number of genes involved in retinal degeneration, preclinical test-
ing of gene therapy approaches for every gene is prohibitive.
Hence, one may envisage that progress towards the development
of therapies for many retinal degenerative diseases may be acceler-
ated by developing the theoretically less risky approach of protein
delivery – administration of which can be readily terminated uponll rights reserved.
phthalmology, Tufts Univer-
, MA 02111, United States.
R. Kumar-Singh).the initial observation of any adverse events. For example,
although viral-mediated gene transfer of ciliary neurotrophic fac-
tor (CNTF) to animal models of retinal degeneration has been doc-
umented to be deleterious (Buch et al., 2006), phase I trials have
been safely completed by use of encapsulated CNTF-producing
cells that could be readily removed from the ocular compartment
of retinitis pigmentosa patients (Sieving et al., 2006).
For some retinal degenerative diseases such as rhodopsin or
peripherin/RDS-associated retinitis pigmentosa (RP), over-expres-
sion of therapeutic gene product may be deleterious, as has been
observed with both viral gene transfer (Sarra et al., 2001) and in
transgenic mice (Tan et al., 2001). Hence, therapies for RP patients
could theoretically be safer by delivery of protein instead of DNA.
In the context of retinal degeneration, which is typically a slow
progressive disease, one may envisage the use of slow release for-
mulations or depots in the intraocular environment for long-term
delivery of therapeutic proteins as has been achieved previously
in some clinical studies (Sieving et al., 2006). However, macromol-
ecules do not readily cross the plasma membrane and do not pen-
etrate neural tissues such as the retina.
Previously, several proteins exhibiting the unusual property of
traversing lipid bilayers have been identiﬁed. These molecules con-
tain protein transduction domains (PTDs) that can be chemically
cross-linked to heterologous proteins, antibodies and enzymes
and facilitate their transport across the plasma membrane
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was ﬁrst reported over a decade ago by Green and Frankel who
independently demonstrated that the Human Immunodeﬁciency
Virus (HIV) TAT protein was able to enter cells when added to
the surrounding media (Frankel & Pabo, 1988; Green & Loewen-
stein, 1988). Subsequently, several other proteins with transducing
capabilities have been identiﬁed, the most intensively studied of
which are the Drosophila homeotic transcription factor ANTP (en-
coded by the antennapedia gene) and the Herpes Simplex Virus
(HSV) VP22 (Elliott & O’Hare, 1997; Joliot, Pernelle, Deagostini-Ba-
zin, & Prochiantz, 1991; Joliot, Triller, Volovitch, Pernelle, & Proch-
iantz, 1991). A variety of additional cell penetrating peptides have
since been discovered (Vives, Schmidt, & Pelegrin, 2008). Apart
from HIV TAT, there is very limited information available on the
performance of PTDs in the retina (Barnett, Elangovan, Bullok, &
Piwnica-Worms, 2006; Cashman, Morris, & Kumar-Singh, 2003;
Dietz, Kilic, & Bahr, 2002; Schorderet et al., 2005).
Previously, we examined the potential use of HIV TAT (Cashman
et al., 2003) and HSV VP22 (Cashman, Sadowski, Morris, Frederick,
& Kumar-Singh, 2002) in delivering recombinant proteins to hu-
man embryonic retinoblasts in culture and to retinal tissues
in vivo. We found that whereas both of these PTDs acted efﬁciently
in vitro, their performance in the retina in vivo was limited. Hence,
we recently developed and described a novel cell and tissue pene-
trating peptide referred to as POD – (peptide for ocular delivery;
GGG[ARKKAAKA]4) that could be used to efﬁciently deliver ﬂuores-
cent dyes or other similarly small molecules into the retina in vivo.
The objective of the current study was to examine the potential
of genetically fusing biologically relevant macromolecules such asFig. 1. De novo synthesized POD–GFP fusion protein localizes to the nucleus. HER cells w
tagged GFP or POD–GFP fusion proteins respectively. Whereas GFP localizes to the cytop
POD–GFP appears to be concentrated in sub nuclear compartments (b, arrowheads). BF,whole proteins to POD in order to determine whether novel trans-
duction properties are conferred upon the recombinant fusion pro-
tein in terms of delivery into the retinal photoreceptors and
interneurons. For proof-of-principle, here we examine delivery of
a POD–GFP fusion protein to retinal cells in vitro, ex vivo and
in vivo. Our results indicate that POD-fusion proteins allow the
penetration and dispersion of macromolecules into a variety of
cells and tissues and hence may have signiﬁcant therapeutic
applications.
2. Results
2.1. De novo synthesized POD–GFP localizes to the nucleus
Transfection of human embryonic retinoblast (HER) cells (Fall-
aux et al., 1996) with pGFPHis, a plasmid expressing a His-tagged
GFP, resulted in relatively diffuse cytoplasmic and nuclear localiza-
tion of recombinant GFP (Fig. 1a). In contrast, transfection of HER
cells with pPODGFPHis, a plasmid expressing a His-tagged POD–
GFP fusion protein, resulted in relatively weak cytoplasmic and
intense nuclear localization (Fig. 1b). Furthermore, POD–GFP
appeared to concentrate in sub nuclear compartments (Fig. 1b,
arrowheads). This pattern of localization associated with POD–
GFP contrasts with that of exogenously added lissamine-conju-
gated POD peptide (L-POD), which we have previously shown to
localize primarily to the cytoplasm in a punctate pattern – reminis-
cent of endocytosis (Johnson, Cashman, & Kumar-Singh, 2007). We
conclude that endogenously expressed POD can act as a nuclear
localization signal for POD-fusion proteins.ere transfected with either pGFPHis (a) or pPODGFPHis (b), plasmids expressing His-
lasm and nucleus (a), POD–GFP localizes primarily to the nucleus (b). Furthermore,
brightﬁeld. Color version of this ﬁgure appears online.
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In order to examine protein transduction by exogenously sup-
plied POD–GFP, expression cassettes coding for His-tagged POD–
GFP or GFP, regulated by a CMV promoter, were cloned into an
E1/E3-deleted human adenovirus serotype 5 vector-AdPODGFPHis
and AdGFPHis respectively (Fig. 2a). POD–GFP and GFP were puri-
ﬁed from adenovirus-infected HER cells and electrophoresed on a
Tris–HCl acrylamide gel. Following silver staining, major bands
were identiﬁed at approximately 32 and 28 Kd, corresponding to
roughly the expected molecular weight of POD–GFP and GFP
respectively (Fig. 2a). Minor bands of slightly greater molecular
weight were also detected for each of the proteins by silver stain-
ing. Western blot analyses of the puriﬁed protein fractions using a
monoclonal antibody against GFP conﬁrmed that the major bands
corresponded to GFP and POD–GFP respectively (Fig. 2a). We con-
clude that recombinant adenovirus vectors can be used to generate
highly enriched preparations of POD-fusion proteins from human
cells.Fig. 2. Recombinant adenovirus vectors expressing POD–GFP and uptake of POD–GFP int
E1 region (DE1) of a ﬁrst generation adenovirus vector. POD was fused to GFP via a ﬂexib
the anticipated molecular weights for POD–GFP and GFP. Anti-GFP western blot conﬁrme
incubated with HER cells for 2 h and GFP-positive cells were counted by FACS (b). POD–G
(c). CMV, cytomegalovirus; 6His, His tag; BGH pA, bovine growth hormone polyadenyla
early regions 1–4 respectively.2.3. Transduction properties of POD–GFP in vitro
Approximately 0.2  106 human lung carcinoma epithelial
(A549) or HER cells were incubated with 10 lg puriﬁed recombi-
nant POD–GFP or GFP protein for 2 h and the number of GFP-posi-
tive cells counted by FACS. A total of 35.3 ± 0.9% and 1.4 ± 0.4% of
A549 cells were GFP-positive when incubated with POD–GFP or
GFP respectively. Similarly, a total of 34.2 ± 3.4% and 1.8 ± 0.4% of
HER cells were GFP-positive when incubated with POD–GFP or
GFP respectively (Fig. 2b). As determined previously for the short
peptide C–POD (Johnson et al., 2007), here we re examined
whether POD–GFP was also internalized and not simply membrane
associated by incubation of transduced cells with trypsin. A total of
33.1 ± 4.1% of cells were GFP-positive following treatment with
trypsin – not signiﬁcantly different to the number of GFP-positive
cells observed in the absence of trypsin, suggesting that POD–GFP
is not membrane associated, but rather, internalized (Fig. 2b). Tox-
icity to cells during protein transduction was measured by uptake
of propidium iodide (PI). A total of 2.8 ± 3.8% or 3.2 ± 2.7% of HERo cells. Expression cassettes coding for POD–GFP or GFP were cloned into the deleted
le polyglycine linker (a). Silver staining of puriﬁed protein indicated major bands of
d that these fusion proteins contained GFP (a). Puriﬁed POD–GFP or GFP protein was
FP entered cells and colocalized in part with Lysotracker, a marker of late endosomes
tion signal; ITR, inverted terminal repeat; MLT, major late transcription unit; E1–E4;
Fig. 3. Transduction properties of POD–GFP following subretinal injection in vivo. POD–GFP or GFP protein was injected into the subretinal space of adult mice. POD–GFP
entered the RPE and photoreceptor cell bodies in the ONL (a) and localized to photoreceptor cell body in a perinuclear, punctate and cytoplasmic manner (arrowheads).
Surface plots of 40 retina indicate relative GFP-ﬂuorescence units across the tissue. GFP-associated signal in GFP-injected eyes was not signiﬁcantly above background auto-
ﬂuorescence associated with uninjected eyes, except in the subretinal space as expected (b). Total ﬂuorescence intensity associated with each experiment is quantiﬁed in (c).
Lysosomal marker IDUA (red) indicated that POD–GFP (green) may not be sequestered in the lysosomes in vivo (d). ONL, Outer nuclear Layer; INL, inner nuclear layer; GCL,
ganglion cell layer; RPE, retinal pigment epithelium. Uninjected, n = 3, GFP and POD–GFP, n = 4.
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respectively, similar to that of untransduced cells (3.6 ± 3.0%). In
contrast to endogenous gene expression, POD–GFP now appeared
in the cytoplasm of HER cells in a punctate pattern (Fig. 2c), similar
to our previous observations with L-POD peptide (Johnson et al.,
2007) and reminiscent of an endocytic mechanism of uptake.
POD–GFP failed to colocalize with ER tracker or DAPI but did colo-
calize in partwith Lysotracker (Fig. 2c), a marker of late endosomes
– suggesting that POD–GFP enters cells by more than one mecha-
nism. We conclude that POD–GFP can transduce cells in culture,
does not signiﬁcantly damage the plasma membrane during entry
and in contrast to endogenous expression, colocalizes in part with
late endosomes.
2.4. Transduction properties of POD–GFP in vivo and ex vivo
Investigation of the transduction properties of POD–GFP in vivo
was performed by subretinal and intravitreal injections in mice. A
total of 8.5 lg puriﬁed POD–GFP or GFP protein was injected into
the subretinal space, i.e. between the retinal pigment epithelium(RPE) and photoreceptors of 6-week-old male C57BL6/J mice. Eyes
were harvested after 6 h and frozen sections examined by ﬂuores-
cence microscopy (Fig. 3). POD–GFP was found to localize to the
subretinal space as expected, but it was also detected in the RPE
and abundantly present in the outer nuclear layer (ONL), i.e. the
location of the photoreceptor cell bodies (Fig. 3a). Depending upon
the extent of retinal detachment that was created during the injec-
tion procedure, transduction of the ONL was found in up to 40% of
the retinal surface (data not shown). Occasional GFP-positive cells
were also noted in the nerve ﬁber layer following subretinal injec-
tion. Closer examination of the photoreceptor cell bodies in the
ONL showed POD–GFP distributed in a diffuse pattern throughout
the cytoplasm, with some punctate ﬂuorescence in the perinuclear
space (Fig. 3a, arrowheads). In contrast, GFP-ﬂuorescence associ-
ated with injection of GFP protein was detectable in the subretinal
space as expected, but was not signiﬁcantly greater than back-
ground auto-ﬂuorescence associated with uninjected eyes
(Fig. 3b). Furthermore, there was no evidence of GFP in any other
part of the retina exceeding that of auto-ﬂuorescence (Fig. 3b). To-
tal GFP-associated ﬂuorescence intensity determined from
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ference in the ﬂuorescence intensity of the GFP-injected eyes rela-
tive to POD–GFP-injected eyes (15.9 ± 4.2 versus 37.4 ± 4.4). The
ﬂuorescence intensity of uninjected eyes was 18.3 ± 3.6 and not
signiﬁcantly different from GFP-injected eyes (Fig. 3c).
To investigate the potential for POD–GFP to escape endosomes
in vivo, retinal sections were stained with an antibody to a-L-idu-
ronidase (IDUA), an enzyme involved in the catabolism of glycos-
oaminoglycans (GAGs) and known to localize to lysosomes (von
Figura & Weber, 1978). IDUA was localized almost exclusively in
a punctate pattern in the perinuclear region of the photoreceptorFig. 4. Transduction Properties of POD–GFP following intravitreal injection in vivo. POD
harvested after 6 h. POD–GFP was detected (a) in the ganglion cells and a subset of cells in
Signiﬁcant GFP-associated ﬂuorescence could not be detected above background auto-ﬂ
associated with each experiment is quantiﬁed in (c). Apparent GFP-signal in uninjecte
observed in GFP-injected eyes. Signiﬁcant binding of POD–GFP to the lens capsule was no
RPE, retinal pigment epithelium. Uninjected, n = 3, GFP and POD–GFP, n = 4. Color versiocell bodies, consistent with a lysosomal localization (Fig. 3d). In
contrast, POD–GFP was dispersed throughout the cell body of the
photoreceptors in the ONL, strongly suggestive of its ability to es-
cape the endosomal compartment.
A total of 6.6 lg puriﬁed POD–GFP or GFP protein was injected
into the intravitreal space, i.e. between the lens and neural retina
of 6-week-old male C57BL6/J mice and eyes were harvested after
6 h and frozen sections examined by ﬂuorescence microscopy.
POD–GFP could be detected in ganglion cells (Fig. 4a) and in a sub-
population of cells in the inner nuclear layer (INL) (Fig. 4a, arrow-
head). In contrast to subretinal injection, there was no POD–GFP–GFP or GFP protein was injected into the intravitreal space of adult mice and eyes
the inner nuclear layer (INL) (arrowhead) and dendrites in the inner retina (arrow).
uorescence associated with uninjected or GFP-injected eyes (b). Total GFP-intensity
d eyes is auto-ﬂuorescence of the outer segments (OS), which was not typically
ted (d). ONL, Outer nuclear Layer; INL, inner nuclear layer; GCL, ganglion cell layer;
n of this ﬁgure appears online.
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auto-ﬂuorescence (Fig. 4a) and the overall number of GFP-positive
cells was signiﬁcantly less than that achieved by subretinal injec-
tion. Closer examination of the inner retina revealed that a large
number of dendrites also contained POD–GFP (Fig. 4a, arrow). Fol-
lowing intravitreal injection, GFP-ﬂuorescence associated with
injection of GFP protein was not greater than auto-ﬂuorescence
associated with uninjected eyes (Fig. 4b). Quantitation of the areas
of transduction by compiling data from two-dimensional surface
plots indicated that the GFP-ﬂuorescence intensity was 20.8 ± 2.9
and 21.4 ± 2.5 arbitrary units for uninjected and GFP-injected eyes
respectively. In contrast, the GFP-ﬂuorescence intensity associated
with POD–GFP-injected eyes was 54.5 ± 7.6, a signiﬁcant (p < 0.01)
increase over both the GFP and uninjected eyes (Fig. 4c).
Following intravitreal injection, we noted that the lens capsule
had a very strong afﬁnity for POD–GFP but not for GFP (Fig. 4d).
The strong afﬁnity of POD–GFP for the lens may have reducedFig. 5. Transduction properties of POD–GFP ex vivo and electroretinograms of POD–GFP-in
for 4 h. Signiﬁcant levels of GFP were detected in the GCL, a subset of cells in the INL (arro
the eyecups of GFP-injected or uninjected animals (b), as conﬁrmed in the accompanyin
untreated, n = 3. Electroretinograms (ERGs) were performed 48 h following subretinal or
amplitude of A and B-waves at the indicated ﬂash intensities following subretinal injectio
GFP and PBS for all light intensities examined. p < 0.05. n = 4 for each protein. GCL, gangl
epithelium. Color version of this ﬁgure appears online.the amount of protein available for retinal transduction. This
may account in part for the poorer transduction of the neural ret-
ina (in terms of number of cells) via the intravitreal route relative
to the subretinal route. Our efforts to inject higher amounts of pro-
tein into the vitreous were thwarted by the limited volume of the
mouse vitreous and a propensity for POD–GFP to aggregate at high
concentrations. Hence, we removed the lens and vitreous and
examined the uptake of POD–GFP or GFP when administered di-
rectly into eyecups ex vivo.
The posterior chamber of the mouse eye was incubated for 4 h
ex vivo with 8.5 lg of POD–GFP or GFP prior to ﬁxing and section-
ing. GFP-associated signal was detected in the ganglion cell layer
(GCL), a subset of cells in the INL (Fig. 5a, arrowhead) and a rela-
tively weak GFP-signal in the ONL of the POD–GFP-treated eyes
(Fig. 5a). There appeared to be a gradient of GFP expression with
the most robust signal located in the GCL and diminishing towards
the ONL (Fig. 5a). No signiﬁcant GFP-associated signal was ob-jected eyes in vivo. POD–GFP or GFP protein was placed in the eyecups of adult mice
whead) and potentially the ONL (a). Relatively lower levels of GFP were detected in
g surface plots. (c) Total GFP-intensity for each fusion protein. POD–GFP, GFP n = 4,
intravitreal injections of POD–GFP, GFP, or PBS (d). Graphical representation of the
n or intravitreal injection indicate no signiﬁcant difference (p > 0.05) between POD–
ion cell layer, INL, inner nuclear layer, ONL, outer nuclear layer, RPE, retinal pigment
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from two-dimensional surface plots revealed that the ﬂuorescence
intensity of the POD–GFP eyes was signiﬁcantly greater than GFP
treated eyes (Fig. 5c); 49.2 ± 10.6 versus 23.5 ± 2.7, (p < 0.01) sug-
gestive of an effective POD-mediated uptake of GFP ex vivo.
In summary, we conclude that POD–GFP delivered to the sub-
retinal space transduces the RPE and photoreceptor cells. In con-
trast, delivery of POD–GFP to the intravitreal space transduces
the ganglion cells and a limited number of cells in the INL, as well
as the lens capsule.2.5. POD–GFP does not cause functional toxicity in vivo
To examine the toxicity of POD–GFP or GFP in vivo, we injected
8.5 lg of either protein into the subretinal space of adult mice.
Similarly, 6.6 lg of either protein was injected intravitreally, fol-
lowed by measurement of the electroretinogram (ERG) after 48 h.
As a negative control we examined the effects of PBS injected in
the same volumes used for POD–GFP or GFP. A and B-wave ampli-
tudes (Fig. 5d) indicated that there was no signiﬁcant difference
between the POD–GFP and the PBS under any of the conditionsFig. 6. Topical application of POD–GFP on murine cornea in vivo. Recombinant POD–GFP o
and harvested 45 min later. Whereas GFP does not substantially bind to ocular tissues an
detected in corneal wholemounts. Transverse sections of cornea indicates that POD–GFP
majority of the signal emanates from the corneal epithelium (b). CE, Corneal Epithelium;or injections tested (p > 0.05). The GFP fusion protein showed a sig-
niﬁcant slight decrease in amplitude of the B-wave compared to
POD–GFP by injection into the subretinal space at 10 dB
(p < 0.05) (Fig. 5d) and compared to both the POD–GFP and PBS
intravitreal injections at 20 dB (p < 0.05) (Fig. 5d). We conclude
that the ERG is not signiﬁcantly altered after 48 h in POD–GFP-in-
jected eyes relative to GFP or PBS injected eyes.2.6. Topical application of POD–GFP to cornea in vivo
A total of 40 lg puriﬁed POD–GFP or GFP protein was topically
applied to the cornea of an anesthetized 6-week-old male
C57BL6/J mouse and eyes harvested 45 min later for sectioning.
Excitation of whole mouse eyes with 474 nm light revealed that
whereas GFP was washed away and therefore absent from the
outer surface of the eye, POD–GFP could be detected on most of
the ocular surface (Fig. 6a). To further examine localization of
POD–GFP, the anterior ocular tissues were dissected and corneas
ﬂat mounted or cross-sectioned and re examined by ﬂuorescence
microscopy. Again, whereas GFP-ﬂuorescence was not detectable
in ﬂat mounts that had been prepared from mice with topicalr GFP proteins were applied to the eyes of anesthetized adult mice and eyes washed
d is not internalized, POD–GFP binds to the entire corneal surface and can be readily
localizes to the corneal epithelium. Surface plots of cross-sections indicates that the
Untreated, n = 3, POD–GFP and GFP, n = 4. Color version of this ﬁgure appears online.
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both ﬂat mounts and cross-sections of corneas from mice that re-
ceived topical application of POD–GFP (Fig. 6b). Transverse sec-
tions revealed that the majority of the GFP-ﬂuorescence
associated with POD–GFP emanated from the corneal epithelium
and minimally from the stroma (Fig. 6a). No GFP-signal was de-
tected in corneal cross-sections prepared from mice that received
topical application of GFP. Quantitation using two-dimensional
surface plots indicated substantially more GFP-signal associated
with tissue following treatment with POD–GFP (28.4 ± 5.9) thanFig. 7. Topical application of POD–GFP to shaved skin in vivo. POD–GFP or GFP protein w
ﬂuorescence, POD–GFP binds to the epidermis (a). Although hair (arrowhead) and papi
portion of this signal is due to auto-ﬂuorescence (b). E, Epidermis; P, Papilla. Untreatedwith GFP (3.5 ± 3.8) or no treatment (1.8 ± 0.7) (Fig. 6b). Again,
the difference between GFP and untreated corneas was not signif-
icant (p > 0.5) whereas the difference between POD–GFP and the
other treatments was signiﬁcant (p < 0.01). Surface plots of cor-
neal application indicated minimal auto-ﬂuorescence in the GFP
or untreated eyes. The signal from the POD–GFP treatment varied
in intensity throughout the epithelium but was generally the
most intense at the center of the section (Fig. 6). We conclude
that topical application of POD–GFP to ocular tissues permits
binding to the corneal epithelium.as applied to the skin for 24 h. Whereas GFP does not bind skin beyond that of auto-
lla of the hair are also GFP-positive in sections exposed to POD–GFP, a signiﬁcant
, n = 3, POD–GFP and GFP, n = 4. Color version of this ﬁgure appears online.
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All of the above data and our previous report describing the prop-
erties of POD focused on retinal or ocular tissues. The success of the
corneal topical application, as well as the potential of this mode of
delivery for therapeutic proteins, prompted us to investigate this
type of application to other tissues. To begin to extend these obser-
vations to other organ systems, we examined the potential of trans
dermal delivery of POD-fusion protein. We topically applied 40 lg
of POD–GFP or GFP to the shaved skin of adult C57BL6/J mice. The
animals were sacriﬁced 24 h later and frozen sections of the treated
region were examined by ﬂuorescence microscopy (Fig. 7a). We
noted that hair follicles and hair within tissues was auto ﬂuorescent
and resulted in an overall GFP-ﬂuorescence signal of 2.3 ± 1.5
(Fig. 7b). Similar to the untreated tissue, GFP-ﬂuorescence associ-
ated with topical application of GFP was 6.6 ± 3.3 (Fig. 7b) whereas
the epidermis of skin prepared from mice that received POD–GFP
was signiﬁcantly GFP-positive (23.4 ± 8.8, p < 0.05) (Fig. 7b). Uptake
of GFP appeared punctate and diffuse but was almost exclusively
associated with the epidermis and not the deeper layers of the skin.
Bindingwas also observed around the hair follicle but this could not
be deﬁnitively separated from auto-ﬂuorescence. We conclude that
while GFP does not signiﬁcantly bind to mouse skin, POD–GFP not
only binds for at least 24 h, but may also potentially be taken up
by the epidermis. Surface plots of transdermal sections indicated
that POD–GFP appeared to cluster at speciﬁc regions on the epider-
mis, resulting in very prominent peaks coupled with lower neigh-
boring peaks, suggesting that the transduction, while effective,
was not uniform (Fig. 7b).3. Discussion
Previously, we examined the potential use of HIV TAT (Cashman
et al., 2003) and HSV VP22 (Cashman et al., 2002) in delivering re-
combinant GFP to retinal tissues in vivo. These studies were the ﬁrst
examplesof theuseof PTDs in the retina andamongst theﬁrst exam-
ples of the use of PTDs in vivo. We found that whereas both of these
PTDs acted efﬁciently in vitro, their performance in vivowas limited.
Hence, recently we turned our attention to identifying alternative
PTDs that may have superior performance in neuronal tissues such
as the retina in vivo. Through the use ofmolecularmodeling,we pre-
viously designed and tested a novel cell and tissue penetrating pep-
tide – POD (Johnson et al., 2007). Previously we demonstrated that
POD could deliver inert molecules such as ﬂuorophores and quan-
tum dots across the plasma membrane of retinal neurons in vivo.
The objective of the current study was to examine the potential of
utilizing POD to deliver biologically relevant macromolecules such
as proteins into retinal neurons including photoreceptors and gan-
glion cells, two principle target cells for retinal degeneration.
For proof-of-principle, we selected to deliver GFP – primarily be-
cause it is endogenously ﬂuorescent and hence permits facile local-
ization in vivo and also because it is not known to be associatedwith
any facilitated transport systems. Furthermore, GFP is an unremark-
ableprotein in termsof itsmolecularweight (27 Kd), allowingus to
reach some general conclusions regarding the relevance of our data
to potentially therapeutic applications. Supporting our previous
observations with the short POD peptide, we found that POD–GFP
was internalized into cells and not simply membrane associated.
We also observed co localization in part with late endosomes
in vitro. POD–GFP did not colocalize with the lysosomal enzyme
IDUA in vivo, indicating that POD–GFP was not sequestered in lyso-
somes at the time point measured here. This is a signiﬁcant ﬁnding
since endosomal/lysosomal escape is a critical obstacle for drug
and/orDNAdeliverybycell penetratingpeptides.Wewere surprised
to observe that endogenously expressed POD–GFP protein localizedto the nucleus. Since the new observations presented here suggest
that POD can also act as a nuclear localization signal, onemay envis-
ageuse for suchaprotein transfer systemthat targets thenucleus for
delivery of for example customzincﬁnger nucleases for gene correc-
tion in vivo (Urnov et al., 2005) or other proteins whose function re-
sides in the nucleus.
In the current study, we demonstrated delivery of a macromol-
ecule to the RPE, retinal photoreceptors and neurons in the inner
nuclear layer. To the best of our knowledge, this is the ﬁrst demon-
stration of direct transduction of photoreceptors by a recombinant
protein in vivo. Injection of the POD–GFP fusion protein into either
the subretinal or intravitreal space did not result in any signiﬁcant
toxicity as measured by ERG. Transduction of photoreceptors with
POD-fusion proteins may have potential applications in the treat-
ment of diseases such as RP, Leber’s congenital amaurosis
(CEP290) etc. whereas transduction of the RPE will have potential
applications in the treatment of diseases such as age related mac-
ular degeneration (AMD). One may also envisage use of POD-fusion
proteins to achieve enhanced penetration of antibodies. For exam-
ple, lucentis or avastin can block the activity of vascular endothelial
growth factor (VEGF) – an approach found to be efﬁcacious in the
treatment of AMD (Pieramici & Avery, 2006). Perhaps a POD-lucen-
tis or POD-avastin fusion protein or a POD-single chain antibody
may be more efﬁcacious than an antibody alone.
Intravitreal injection allowed targeting of the ganglion cells,
degeneration of which is associated with glaucoma – one of the
leading causes of blindness in the working population (Sample,
Bosworth, & Weinreb, 2000). Degeneration of ganglion cells is also
a well-established model for testing CNS-targeted therapies. For
example, in a model of traumatic injury in the CNS, optic nerve
axotomy, TAT–GDNF reduced the number of activated caspase-3-
positive cells and increased the survival of retinal ganglion cells
relative to GDNF alone (Kilic, Kilic, Dietz, & Bahr, 2004). Perhaps
POD–GDNF fusion protein will have potential use in the treatment
of disorders of the central nervous system (CNS). Efﬁcacy of GDNF
is limited in part due to the inability of this macromolecule to dis-
perse in tissues (Salvatore et al., 2006) – a problem that may poten-
tially be addressed by use of a POD–GDNF fusion protein.
We observed relatively strong binding of POD–GFP to the lens
capsule. This is not surprising given that the lens capsule contains
abundant levels of heparan sulphate proteoglycans (Rossi et al.,
2003;Winkler, Wirbelauer, Frank, & Laqua, 2001), a putative recep-
tor for POD (Johnson et al., 2007). Accordingly, studies performed
ex vivo using murine eyecups indicated superior transduction of
photoreceptor cell bodies in the absence of vitreous and lens.
Delivery of POD–GFP to the corneal epithelium represents a po-
tential means to improve efﬁcacy and delivery of drugs or proteins
for the treatment of diseases of this tissue, including dry eye and
infections such as Herpes Zoster. Delivery of drugs to ocular tissues
via topical administration to the cornea is common practice, how-
ever, drainage of the majority of the drug occurs via the lacrimal
ducts and hence reduces drug potency and activity. Prolonged
binding of drugs to the ocular surface may increase their bioavail-
ability, but this remains to be determined.
In thepastwehave speculatedon theusefulness of PODandasso-
ciated fusion proteins in areas beyond ophthalmology. Here we de-
scribed a potential role for POD-mediated protein delivery to the
integumentary system. Application of POD–GFP to the skin pro-
duced intriguing results that suggested POD-fusion proteins might
be useful in treating diseases of the skin. However, while POD–GFP
successfully localized to the epidermis, it failed to penetrate into
the dermal layer. Nonetheless,we are encouraged by these initial re-
sults because the binding and possible internalization of POD–GFP
persisted for at least 24 h. Additional studies will be necessary to
determine if longer treatment times and multiple applications
may result in deeper penetration of POD–GFP into the skin.
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protein and shown, in support of our original hypothesis that a
POD-fusion protein may be an effective transducer of cells and ocu-
lar tissues in vivo. Importantly, we demonstrated localization of
POD–GFP to the photoreceptor cell bodies and ganglion cells, pav-
ing the way for future studies to examine use of POD-fusion pro-
teins in animal models of retinal degeneration. Also, we showed
for the ﬁrst time that POD has applications outside of the eye by
performing trans dermal topical application. The success of
POD–GFP binding to the skin coupled with the promising results
obtained from ocular injections suggest that there are numerous
organ systems and diseases in which POD may be a useful delivery
agent. Although initial studies are very promising, further studies
will need to be performed to for example, achieve cellular targeting
speciﬁcity and determine how long the delivered protein can re-
main in the target cell as well as more clearly deﬁne any toxicity
associated with POD–GFP.
4. Materials and methods
4.1. Cell culture and transfection
Human embryonic retinoblast (HER) cells were cultured using
previously described methods (Fallaux et al., 1996). Carcinoma hu-
man alveolar basal epithelial cells (A549, American Type Culture
Collection, Manassas, VA) were grown to 70–80% conﬂuence in
DMEM media supplemented with 10% fetal bovine serum (FBS).
All experimental cell culture procedures were performed in DMEM
supplemented with 2% FBS. Transfection of plasmids was carried
out using 2:1 ll Lipofectamine: lg plasmid in Opti-MEM media.
Forty-eight hours post-transfection, the cells were ﬁxed and
stained with 40,6-diamidino-2-phenylindole (DAPI).
4.2. Plasmid and adenovirus construction
Oligonucleotides POD-upper and POD-lower coding for the POD
protein transduction domain were cloned into SacI/EcoRI digested
pQBI25fA1 (Qbiogene, Carlsbad, CA) to generate pPODGFP.
pPODGFPHis and pGFPHis were cloned by inserting the oligonucle-
otides His-upper and His-lower into ClaI/MluI digested pPODGFP
and pQBI25fA1, respectively. pPODGFPHis and pGFPHis were di-
gested with BglII and XmnI and ligated with BglII/EcoRV-digested
pShuttle. The corresponding pShuttle plasmids were linearized
with PmeI, gel puriﬁed, and cotransfected with pAdEasy-1into
E. coli BJ5183 cells. Recombinant plasmids were digested with PacI
and transfected into HER cells. AdPODGFPHis and AdGFPHis were
isolated using a virus puriﬁcation kit (Puresyn, Malvern, PA).
POD-upper: GCCACCATGGCTCGTAAGAAGGCTGCTAAGGCTGCCC
GCAAGAAGGCTGCCAAGGCCGCACGAAAGAAGGCAGCAAAGGCG
GCTCGTAAGAAGGCTGCCAAGGCGTC
POD-lower: AATTGACGCCTTGGCAGCCTTCTTACGAGCCGCCTTTG
CTGCCTTCTTTCGTGCGGCCTTGGCAGCCTTCTTGCGGGCAGCCTTA
GCAGCCTTCTTACGAGCCATGGTGGCGC
His tag-upper: CGATCATCATCACCATCACCATTGA
His tag-lower: CGCGTCAATGGTGATGGTGATGATGATPOD and His tag sequences are indicated in bold.
4.3. Protein isolation and puriﬁcation
HER cells were infected with either AdPODGFPHis or AdGFPHis
at a multiplicity of infection (MOI) of 200 viral particles/cell. Cells
were harvested when greater than 90% of cells were GFP-positive
as determined by ﬂuorescence microscopy which occurred approx-
imately 96 h post-infection. The cytoplasm and nucleus were iso-lated and lysed for protein puriﬁcation using the NuCLEAR
Extraction Kit (Sigma, St. Louis, MO). Fusion proteins were isolated
using the His-Select kit (Sigma) and 250 mM imidazole according
to manufacturer’s instructions. The ﬁnal protein eluates were dia-
lyzed in PBS using a 10 K Ultrafree column (Millipore, Billerica,
MA). Protein concentrations were measured using a Bradford assay
(Bio-Rad, Hercules, CA). To eliminate the potential of virus contam-
ination in the protein prep, fusion proteins were heated to 70 C for
5 min to inactivate any residual virus and tested for cytopathic ef-
fect in HER cells.
4.4. Cellular uptake and localization of PODGFPHis
To evaluate cellular penetration of POD-fusion proteins, HER
cells were seeded on Lab Tek-II chamber slides and incubated with
10 lg of POD–GFP or GFP for 2 h. Following ﬁxation, cells were
visualized by light and ﬂuorescence microscopy using an Olympus
BX51 microscope with differential interference contrast (DIC) and
the appropriate ﬂuorescence ﬁlters. Images were captured using
a Retiga 2000R FAST camera and QCapture Pro 5.0 (QImaging, Brit-
ish Columbia, Canada). To quantitate protein uptake, 0.2  106 of
either HER or A549 cells were incubated with 10 lg POD–GFP or
GFP for 2 h. Cells were washed with PBS, pelleted and resuspended
in PBS for FACS analysis. Protein internalization was differentiated
from membrane binding as described previously (Johnson et al.,
2007). Brieﬂy, HER cells were treated with POD–GFP as above fol-
lowed by trypsin (2.5 mg/ml) for 12 min prior to FACS analysis. Cell
membrane integrity was evaluated by measuring the percentage of
Propidium Iodide (1 lM) positive cells in the presence of fusion
protein. FACS analysis of protein uptake, internalization and toxic-
ity was performed using a FACSCAlibur (Becton Dickinson, Franklin
Lakes, NJ) and results analyzed using CellQuest Pro (Becton Dickin-
son). 10,000 events were counted for each experiment, which was
performed in triplicate and repeated.
HER and A549 cells were treated as above before the addition of
LysoTracker, ER Tracker (Molecular Probes, Carlsbad, CA), or DAPI
for one hour. These reagents were removed and cells ﬁxed with
formalin for imaging.
4.5. Silver staining and Western blotting
1 lg of POD–GFP and 250 lg of recombinant GFP were loaded
onto a 12% Tris–HCl gel (Bio-Rad). Silver staining was carried out
using Silver Stain Plus Kit (Bio-Rad, Hercules, CA). For Western
blotting, proteins were transferred to PVDF membranes, which
were probed for GFP expression using anti-AFP 5001 11E5 mono-
clonal antibody (MP Biomedicals, Solon, OH) and HRP-conjugated
goat anti-mouse secondary antibody. The signal was detected
using SuperSignal West Pico chemiluminescent substrate (Pierce,
Rockford, IL).
4.6. Delivery of PODGFPHis to ocular tissues ex vivo and in vivo
The use of animals in this study was in accordance with the
ARVO Statement for the Use of Animals in Opthalmic and Vision
Research. Ex vivo applications were performed as described previ-
ously (Johnson et al., 2007). Brieﬂy, C57BL/6 mice were sacriﬁced
and the eyes were enucleated. The cornea and lens were removed
and the posterior chamber was washed with PBS prior to incuba-
tion with 8.5 lg of PODGFPHis or GFPHis in 2% DMEM for 4 h at
37 C. Eyes were washed with PBS, ﬁxed in 4% paraformaldehyde
and prepared for sectioning.
Subretinal and intravitreal injections of the fusion proteins
were performed using previously described techniques (Cashman,
Bowman, Christofferson, & Kumar-Singh, 2006). Brieﬂy, 8.5 lg of
POD–GFP or 6.6 lg of GFP protein was injected into the subretinal
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Four independent injections were performed and yielded nearly
identical results. Six hours post-injection, mice were sacriﬁced by
CO2 inhalation and cervical dislocation. For topical delivery of the
PODGFPHis or GFPHis, C57BL6/J mice were anesthetized with xyla-
zine/ketamine and 2 ll containing 40 lg of protein were dropped
onto the corneal surface. Forty-ﬁve minutes following administra-
tion, mice were sacriﬁced as above and eyes enucleated, washed
twice in PBS, and ﬁxed overnight in 4% paraformaldehyde. Eyes
were embedded in Optimal Cutting Temperature Compound (Sak-
ura Finetek, Torrance, CA) and 14 lm sections were collected using
a Microm 550 cryostat.
4.7. Immunocytochemistry
Lysosomal identiﬁcation was carried out by staining eye sec-
tions with a rabbit polyclonal antibody to IDUA (BP13, BioMarin
Pharmaceutical Inc.) at a dilution of 1:100. Sections were blocked
with 5% non-fat milk in PBS with 0.25% Triton X-100 before over-
night incubation at 4 C with the primary antibody. The sections
were washed three times with PBS and incubated with a Cy3 goat
anti-rabbit secondary antibody (Jackson ImmunoResearch) for
1.5 h. The sections were again washed three times with PBS and al-
lowed to dry prior to imaging. To examine antibody speciﬁcity and
non-speciﬁc binding of the secondary, additional sections were
treated as described above in the absence of primary antibody.
No ﬂuorescence was detected in these sections.
4.8. Electroretinography
Mice were injected with either the fusion proteins POD–GFP,
GFP or an equal volume of PBS into the subretinal (8.5 lg) or intra-
vitreal (6.6 lg) space and analyzed by electroretinography (ERG)
48-h after injection. Mice were dark-adapted overnight, anesthe-
tized as described above and pupils dilated with 1% Tropicamide
(Akorn, Inc., Lake Forest, IL). Scotopic ERGs were recorded at three
different ﬂash intensities (20, 10 and 0 dB) using contact lens
electrodes and the UTAS system with BigShot ganzfeld (LKC Tech-
nologies, Inc., Gaithersburg, MD). 5–10 ﬂashes were averaged for
the high–low intensities. A and B-waves were measured at 10
and 0 dB and the B-wave at 20 dB. Signiﬁcance was analyzed
using a Student’s t-test. For all conditions n = 4, except in the intra-
vitreal GFP fusion protein condition for which n = 3.
4.9. Transdermal application
Adult mice were anesthetized as described above and the abdo-
men shaved to reveal a 2.25 cm2 area of skin. 40 lg of protein was
applied to the skin for 24 h. Upon completion of the treatment, ani-
mals were sacriﬁced and the treated skin dissected and ﬁxed over-
night in 4% paraformaldehyde and transverse sections were
obtained as described above.
4.10. Quantitation of protein transduction
Images of untreated tissue or tissue treated with POD–GFP or
GFP were captured as above. Untreated tissue was included to as-
sess auto-ﬂuorescence. Image J (National Institutes of Health) con-
verts image pixels into brightness values, which are reported here
for quantitation and comparison purposes. Identical regions of
each image were measured for each application and plotted as
arbitrary units of brightness. Signiﬁcant differences in brightness
were determined using the Student’s t-test with a p-value of less
than 0.05 being recorded as signiﬁcant. Surface plots were gener-
ated using Image J.Acknowledgments
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